Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; Maerz, Winfried; Masana, Luis; Mello e Silva, Alberto; Reiner, Zeljko; Ros, Emilio; Vrablik, Michal; Zambon, Alberto; Zamorano, Jose; Stock, Jane; Tokgozoglu, Lale; Catapano, Alberico

doi:10.1016/j.atherosclerosis.2021.03.039

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Atıf İçin Kopyala

Averna M., Banach M., Bruckert E., Drexel H., Farnier M., Gaita D., ...Daha Fazla

ATHEROSCLEROSIS, cilt.325, ss.99-109, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 325
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.atherosclerosis.2021.03.039
Dergi Adı: ATHEROSCLEROSIS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.99-109
Hacettepe Üniversitesi Adresli: Evet

Özet

Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients.